BRPI0408004A - composições e métodos para diagnóstico e tratamento de asma ou outras doenças alérgicas ou inflamatórias - Google Patents

composições e métodos para diagnóstico e tratamento de asma ou outras doenças alérgicas ou inflamatórias

Info

Publication number
BRPI0408004A
BRPI0408004A BRPI0408004-1A BRPI0408004A BRPI0408004A BR PI0408004 A BRPI0408004 A BR PI0408004A BR PI0408004 A BRPI0408004 A BR PI0408004A BR PI0408004 A BRPI0408004 A BR PI0408004A
Authority
BR
Brazil
Prior art keywords
component
allergic
asthma
inflammatory diseases
methods
Prior art date
Application number
BRPI0408004-1A
Other languages
English (en)
Inventor
Michael R Bowman
Debra Ellis
Maximillian T Follettie
Aaron Winkler
Cara Williams
Hang Chen
Wei Liu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0408004A publication Critical patent/BRPI0408004A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001—Arginase (3.5.3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)

Abstract

"COMPOSIçõES E MéTODOS PARA DIAGNóSTICO E TRATAMENTO DE ASMA OU OUTRAS DOENçAS ALéRGICAS OU INFLAMATóRIAS". A presente invenção refere-se a composições e métodos úteis para detectar ou tratar asma ou outras doenças alérgicas ou inflamatórias. Em um aspecto, os métodos da presente invenção incluem inibir a atividade ou expressão de um componente de uma trilha metabólica de arginina em tecidos afetados por asma ou outras doenças alérgicas ou inflamatórias. Em muitas modalidades, o componente sendo inibido é um transportador de aminoácido catiónico, uma arginase, ou um componente a jusante da arginase. Em muitas outras modalidades, a atividade ou expressão do componente é inibida por um agente que liga-se ao componente. Em ainda muitas outras modalidades, a atividade ou expressão do componente é inibida por um agente que liga-se a um polinucleotídeo codificando o componente.
BRPI0408004-1A 2003-03-04 2004-03-04 composições e métodos para diagnóstico e tratamento de asma ou outras doenças alérgicas ou inflamatórias BRPI0408004A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45139603P 2003-03-04 2003-03-04
US47587003P 2003-06-05 2003-06-05
PCT/US2004/006470 WO2005003164A2 (en) 2003-03-04 2004-03-04 Compositions and methods for diagnosing and treating asthma or other allergic or inflammatory diseases

Publications (1)

Publication Number Publication Date
BRPI0408004A true BRPI0408004A (pt) 2006-02-14

Family

ID=33567303

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408004-1A BRPI0408004A (pt) 2003-03-04 2004-03-04 composições e métodos para diagnóstico e tratamento de asma ou outras doenças alérgicas ou inflamatórias

Country Status (11)

Country Link
US (2) US20040234517A1 (pt)
EP (1) EP1599587A2 (pt)
JP (1) JP2007537984A (pt)
KR (1) KR20050106483A (pt)
AU (1) AU2004253846A1 (pt)
BR (1) BRPI0408004A (pt)
CA (1) CA2517684A1 (pt)
MX (1) MXPA05009251A (pt)
NO (1) NO20054336L (pt)
RU (2) RU2005130636A (pt)
WO (1) WO2005003164A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090298912A1 (en) * 2005-07-01 2009-12-03 The Johns Hopkins University Arginase II: A Target treatment of aging heart and heart failure
US20100021953A1 (en) * 2005-08-03 2010-01-28 Astrazeneca Ab Method for Identifying an Agent that Modulates Arginine Transport in a Chondrocyte
US20070082865A1 (en) * 2005-10-11 2007-04-12 Washington University Compositions and methods for treatment of airway hypersecretion
EP2083812B1 (en) * 2006-11-21 2017-04-05 Rijksuniversiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
US20090155784A1 (en) * 2007-01-22 2009-06-18 Wyeth Assessment of asthma and allergen-dependent gene expression
EP1967187B1 (fr) * 2007-03-06 2011-04-06 Rachid Ennamany Composition à base de rutine et de L-lysine
US8541183B2 (en) 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
ES2703714T3 (es) * 2009-03-12 2019-03-12 Cancer Prevention & Cure Ltd Métodos de identificación, evaluación, prevención y terapia de enfermedades pulmonares y kits de los mismos, incluida la identificación, evaluación, prevención y terapia de enfermedades en base al género
GB201007556D0 (en) * 2010-05-06 2010-06-23 Wetenschappelijk En Tech Ct Va Methods and compositions for textile layers and coatings
EP2576783B1 (en) * 2010-05-26 2017-11-29 CuRNA, Inc. Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
KR102008708B1 (ko) * 2010-06-23 2019-08-08 큐알엔에이, 인크. 전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료
CN113144178B (zh) 2014-04-29 2024-10-18 康达医药科技有限公司 采用精氨酸酶i调节免疫系统的方法和组合物
CN110709936A (zh) 2017-04-04 2020-01-17 肺癌蛋白质组学有限责任公司 用于早期肺癌预后的基于血浆的蛋白质概况分析
MX2023002285A (es) * 2020-08-26 2023-05-16 Cila Therapeutic Inc Agentes terapeuticos inhalables.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
ATE75483T1 (de) * 1981-10-23 1992-05-15 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4625014A (en) * 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) * 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5266464A (en) * 1988-02-10 1993-11-30 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US5688655A (en) * 1988-02-10 1997-11-18 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US4980281A (en) * 1988-02-10 1990-12-25 Housey Gerard M Method of screening for protein inhibitors and activators
US5459039A (en) * 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US5866123A (en) * 1990-04-13 1999-02-02 Research Development Foundation Gene encoding cationic amino acid transporter protein
US6784163B1 (en) * 1990-04-13 2004-08-31 Macleod Carol L. Inhibition of cationic amino acid transporter protein and uses thereof
GB9509757D0 (en) * 1995-05-13 1995-07-05 Ilford Ltd Toning of photographic print material
EP1351675A2 (en) * 2000-08-24 2003-10-15 The Regents of the University of California Alpha-difluoromethylornithine (dfmo) use in the human prostate
US20030166562A1 (en) * 2002-03-01 2003-09-04 Rothenberg Marc Elliot Treatment for asthma or allergies
WO2003078578A2 (en) * 2002-03-12 2003-09-25 Lsu Medical Center Modulation of the immune response through the manipulation of arginine levels
JP4723476B2 (ja) * 2003-02-14 2011-07-13 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 上昇したアルギナーゼ状態を含む、低下した一酸化窒素バイオアベイラビリティに関連する状態の治療

Also Published As

Publication number Publication date
WO2005003164A9 (en) 2006-07-20
KR20050106483A (ko) 2005-11-09
WO2005003164A2 (en) 2005-01-13
MXPA05009251A (es) 2005-10-19
WO2005003164A3 (en) 2005-05-12
NO20054336D0 (no) 2005-09-20
EP1599587A2 (en) 2005-11-30
AU2004253846A1 (en) 2005-01-13
US20040234517A1 (en) 2004-11-25
NO20054336L (no) 2005-12-02
JP2007537984A (ja) 2007-12-27
US20090156537A1 (en) 2009-06-18
RU2008145510A (ru) 2010-05-27
RU2005130636A (ru) 2006-05-10
CA2517684A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
BRPI0408004A (pt) composições e métodos para diagnóstico e tratamento de asma ou outras doenças alérgicas ou inflamatórias
BR112022020539A2 (pt) Compostos específicos para proteína s de coronavírus e usos dos mesmos
Huang et al. Effects of genistein, apigenin, quercetin, rutin and astilbin on serum uric acid levels and xanthine oxidase activities in normal and hyperuricemic mice
BRPI0810118A8 (pt) Método para tratar doença, método para efetuar profilaxia contra caa, uso de um agente, método para reduzir amilóide vascular em um paciente, e, kit para tratamento
BR112015007780A2 (pt) molécula de anticorpo anti-lingo-1, seu uso para tratamento de distúrbios desmielinantes, kit e composição embalada
BRPI0710485B8 (pt) composições líquidas úteis no tratamento de doenças respiratórias
BR0213817A (pt) Tratamento de sìndrome de resistência à insulina e diabete do tipo 2 com inibidores da pde9
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
BRPI0700678A (pt) método para aperfeiçoar comportamentos de sono
BR112012026249A2 (pt) composto, formulação radiofarmacêutica, composição farmacêutica, uso do composto, mistura, métodos de coletar dados para o diagnóstico de uma doença ou condição associadascom amiloide, de determinar a extensão de carga amiloidogênica de placas em um tecido e/ou um fluido corporal, de coletar dados para determinar uma predisposição a uma doença ou condição associadas com amiloide em um paciente, de coletar dados para monitorar a doença residual mínima em um paciente seguindo o tratamento com um anticorpo ou uma composição de vacina, de coletar dados para predizer capacidade de reação de um paciente sendo tratado com um anticorpo ou uma composição de vacina, e, kit de teste.
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
BRPI0618918B8 (pt) uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
BRPI0514420A (pt) peptìdeo, variante do mesmo, ou um sal farmaceuticamente aceitável do mesmo, composição, uso de um peptìdeo ou de uma variante de peptìdeo, substrato, e, métodos de tratamento ou prevenção de um infecção microbiana, e de tratamento de uma ferida em um indivìduo
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
BR112012006010A2 (pt) composto de glicina
BRPI1012219B8 (pt) produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina
BR0211468A (pt) Métodos de tratar e de prevenir uma doença inflamátoria em um mamìfero e de identificar um composto útil para tratar uma doença inflamatória em um mamìfero, composto, e kits para tratar e para prevenir uma doença inflamatória em um mamìfero
BRPI0415753A (pt) método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm
BR112015022650A8 (pt) inibidores de quinase induzível por sal macrocíclico.
BRPI0409199A (pt) composição para a prevenção ou tratamento de doenças alérgicas usando extrato de arroz preto e seu uso terapêutico
BRPI0410222A (pt) tratamento de distúrbios bipolares e sintomas associados
MA29397B1 (fr) Methode de traitement ou de prevention du diabete de type 2
BRPI0411665A (pt) uso de agomelatina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica ou kit, e, métodos para o tratamento de doenças ou distúrbios responsivos a um inibidor da recaptação de serotonina e para aumentar e/ou proporcionar inìcio mais rápido do efeito terapêutico de um inibidor da recaptação de serotonina
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.